MiMedx Group, Inc. (MDXG) fair value analysis
Nasdaq · Updated 2026-10-19
MDXG price how computed
Forward Fair Value verdict
OvervaluedMDXG is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $4.43
- Sector
- Healthcare
- 12-month range
- $3.08–$7.96
- Market cap
- $646M
- From 52-week high
- -44.3%
- Shares outstanding
- 146M
- Rank in Healthcare by discount to fair value
- #93 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
MiMedx Group, Inc. is a regenerative medicine company that develops and distributes human cellular and tissue-based products for use in surgical and wound care applications. The company operates primarily in the United States, serving healthcare providers and patients through its portfolio of biological products.
MDXG currently ranks #93 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $646M
- P/E (trailing)
- 23x
- Revenue (TTM)
- $355M
- Net margin
- 1.8%
- EPS (TTM)
- $0.19
- Gross margin
- 69.0%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- -7.1%
- Shares outstanding
- 146M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $4.55
- 200-day average
- $4.39
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-28 (post-market)
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-66.7%)
2026-03 ▼ miss (-25.0%)
2025-12 ▲ beat (+50.7%)
2025-09 ▲ beat (+87.5%)
2025-06 ▲ beat (+66.7%)
2025-03 ▼ miss (-16.7%)
2024-12 ▼ miss (-6.7%)
2024-09 ▲ beat (+40.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $7.4
- Target vs last price
- +67.0%
What our data shows for MDXG
- Our model validated 11 trailing price-to-earnings windows for MDXG, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $3.08–$7.96.
- The 14-day relative strength index sits at a neutral 37.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MDXG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MDXG news
TickrTrends' derived news-sentiment signal for MDXG is currently leaning positive, computed from recent coverage.
- MiMedx (MDXG) Merger with Sanara MedTech Faces FTC Second Request, Extending Review (gurufocus.com, 2026-10-16)
TickrTrends take: The FTC's second request regarding MiMedx's proposed merger with Sanara MedTech introduces regulatory uncertainty that could extend the timeline for deal completion and impact the combined entity's near-term financial trajectory. Given TickrTrends' current overvalued assessment of MDXG, investors should monitor whether prolonged regulatory review affects the company's ability to realize projected synergies or requires material adjustments to deal terms. The delayed merger resolution adds an additional risk factor to consider alongside the existing valuation concerns in the healthcare sector context. - MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026 (manilatimes.net, 2026-10-14)
TickrTrends take: MIMEDX is scheduled to present its third quarter 2026 results on October 28, 2026, which will provide investors with updated financial performance data for the Healthcare sector company. Given TickrTrends' current overvalued assessment of MDXG, the upcoming earnings call represents a critical opportunity for the market to evaluate whether the company's operational performance justifies its present valuation or signals a need for downward price adjustment. Valuation-focused investors should monitor whether management's guidance and actual results demonstrate sufficient growth or profitability improvements to support the stock's current market positioning. - MDXG Looks 21.5% Undervalued on GF Value™ After Favorable FDA Ruling (gurufocus.com, 2026-09-23)
TickrTrends take: MDXG received a favorable FDA ruling that prompted a valuation analysis suggesting the stock trades below its calculated GF Value, yet TickrTrends currently assesses the Healthcare company as overvalued based on its own methodology. Investors focused on valuation metrics should note the divergence between these two analytical approaches, as the FDA development represents a material corporate event that may warrant reassessment of fundamental assumptions. The gap between these competing valuations highlights the importance of understanding which metrics and timeframes different analysis frameworks prioritize when evaluating healthcare sector companies.
More MDXG news
- MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter (manilatimes.net, 2026-09-23)
- MDXG Maintains Buy Rating by Craig-Hallum -- Price Target Raised to $8.00 (gurufocus.com, 2026-08-27)
What people are saying
Follow the MDXG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MDXG's sector discount rank declined this week, moving from number 100 to number 110 among Healthcare sector peers. This downward shift in ranking reflects a widening valuation gap relative to comparable companies in the Healthcare sector. The stock maintains an overvalued assessment according to TickrTrends' current valuation verdict.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MDXG showed movement this week within the Healthcare sector. The quality grade improved from D to B, while the sector discount rank declined from number 97 to number 102. The stock maintains an overvalued valuation verdict.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MDXG stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), MDXG is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is MDXG's TickrTrends verdict?
MDXG's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does MDXG compare to other Healthcare stocks?
MDXG ranks #93 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is MDXG overbought or oversold?
MDXG's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does MDXG report earnings next?
MDXG's next earnings report is scheduled for 2026-10-28 (post-market), per the published earnings calendar.
Does MDXG usually beat earnings estimates?
Over its last 8 reported quarters MDXG beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MDXG?
Of 5 analysts covering MDXG, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $7.4 (+67.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
MDXG vs ALKS · MDXG vs CDNA · MDXG vs CRL · MDXG vs HUM · MDXG vs ILMN